GW Henssler & Associates Ltd. cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,696 shares of the medical research company’s stock after selling 1,681 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Thermo Fisher Scientific were worth $7,093,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Gradient Investments LLC raised its stake in shares of Thermo Fisher Scientific by 1,887.5% in the fourth quarter. Gradient Investments LLC now owns 159 shares of the medical research company’s stock valued at $36,000 after buying an additional 151 shares during the period. IMS Capital Management bought a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $53,000. Cornerstone Advisors Inc. raised its stake in shares of Thermo Fisher Scientific by 33.3% in the third quarter. Cornerstone Advisors Inc. now owns 332 shares of the medical research company’s stock valued at $81,000 after buying an additional 83 shares during the period. Legacy Financial Advisors Inc. raised its stake in shares of Thermo Fisher Scientific by 77.2% in the fourth quarter. Legacy Financial Advisors Inc. now owns 450 shares of the medical research company’s stock valued at $101,000 after buying an additional 196 shares during the period. Finally, Banco de Sabadell S.A bought a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $122,000. Hedge funds and other institutional investors own 86.88% of the company’s stock.
TMO has been the topic of several research reports. UBS Group initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, October 9th. They issued a “buy” rating and a $295.00 target price on the stock. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 target price on the stock in a research note on Monday, October 1st. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $242.00 to $254.00 and gave the company an “overweight” rating in a research note on Wednesday, October 10th. Cleveland Research lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Thursday, October 18th. Finally, Barclays boosted their target price on Thermo Fisher Scientific from $250.00 to $275.00 and gave the company an “overweight” rating in a research note on Monday, September 24th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and an average target price of $271.10.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 24th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.55 by $0.07. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The company had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.70 billion. During the same period in the previous year, the company posted $2.31 EPS. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. Equities analysts predict that Thermo Fisher Scientific Inc. will post 11.05 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, January 15th. Investors of record on Monday, December 17th were paid a dividend of $0.17 per share. The ex-dividend date was Friday, December 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 7.17%.
In related news, insider Gregory J. Herrema sold 17,235 shares of the business’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $247.00, for a total transaction of $4,257,045.00. Following the sale, the insider now directly owns 26,446 shares in the company, valued at approximately $6,532,162. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Tyler Jacks sold 1,100 shares of the business’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $251.98, for a total value of $277,178.00. Following the sale, the director now owns 5,879 shares in the company, valued at $1,481,390.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,607 shares of company stock worth $7,972,085. 0.49% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “GW Henssler & Associates Ltd. Lowers Holdings in Thermo Fisher Scientific Inc. (TMO)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.com-unik.info/2019/01/22/gw-henssler-associates-ltd-lowers-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: How Do Front-End Loads Impact an Investment?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.